APOE and amyloidosis: The Plasma test for Amyloid Risk Screening (PARIS) study, a C2N sponsored prospective and controlled study, enrolled patients with amyloid PET imaging obtained as part of the IDEAS (Imaging Dementia Evidence for Amyloid Scanning) study [39], was recently completed and tested concordance between plasma Aβ42/40, ApoE, age and amyloid PET status (central read) in patients who met the IDEAS inclusion criteria (NCT02420756).